Smart radiation seeks out lung cancer cells in new trial
NCT ID NCT06228482
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial is testing a pair of radioactive drugs designed to find and attack non-small cell lung cancer that has spread. First, a scanning drug highlights tumors. Then, a therapeutic drug delivers radiation directly to those tumors. The study will enroll 40 adults whose cancer has worsened despite standard treatments.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Radioactive drugs [68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G
- What this could lead to
- If it works, this could offer a new targeted treatment option for people with advanced lung cancer that has spread.
- What could go wrong
- This is an early Phase 1 trial with only 40 people, so it's too soon to know if it works. The treatment involves radiation, which can cause side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC NONSMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The University of California Davis Comprehensive Cancer Center
RECRUITINGSacramento, California, 95817, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.